Alnylam Pharmaceuticals

ALNY | NASDAQ | 1 Followers
$291.86 +2.30% $6.55
Follow
Overview Metrics Financials
Loading...

Fair Price

$834.87
Overvalued by 96.2%
To display the fair price of a share, you need to be a member of Bulios Black.

Profile

Alnylam Pharmaceuticals, Inc. is an American biotechnology company headquartered in Cambridge, Massachusetts. It focuses on the development of RNA-based therapeutics for the treatment of genetic diseases. The company specializes in RNA interference (RNAi) technology, which allows for the suppression of specific genes expression to treat genetic diseases at the gene level. Their research and development efforts target the treatment of various genetic diseases, including liver, kidney, muscle, and nervous system disorders. Alnylam Pharmaceuticals is known for its innovative approach to RNAi research and development of therapeutic agents for the treatment of rare diseases. The company collaborates with academic institutions, biotechnology firms, and pharmaceutical companies worldwide. Shares of Alnylam Pharmaceuticals, Inc. are publicly traded on the NASDAQ stock exchange.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade